Search

Author/Creator Boulet, Thomas

1. Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer. Issue 13 (14th April 2020)

Authors:
Conte, PierFranco; Schneeweiss, Andreas; Loibl, Sibylle; Mamounas, Eleftherios P.; von Minckwitz, Gunter; Mano, Max S.; Untch, Michael; Huang, Chiun‐Sheng; Wolmark, Norman; Rastogi, Priya; D'Hondt, Veronique; Redondo, Andrés; Stamatovic, Ljiljana; Bonnefoi, Hervé; Castro‐Salguero, Hugo; Fischer, ...
Journal:
Cancer
Issue:
Volume 126:Issue 13(2020)
Page Start:
3132
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study. Issue 5 (10th February 2022)

Authors:
Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Hervé; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiy...
Journal:
Journal of clinical oncology
Issue:
Volume 40:Issue 5(2022)
Page Start:
438
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search